Fate Therapeutics, Inc.

Contributing Author

Recent Articles by Fate Therapeutics, Inc.

Dec-08	Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs FATE GlobeNewswire
Nov-25	Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference FATE GlobeNewswire
Nov-13	Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates FATE GlobeNewswire
Nov-04	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire
Oct-26	Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy FATE GlobeNewswire
Oct-14	Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer FATE GlobeNewswire
Oct-02	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire
Sep-03	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire
Aug-25	Fate Therapeutics to Present at Upcoming Investor Conferences FATE GlobeNewswire
Aug-12	Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates FATE GlobeNewswire
Aug-05	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire
Jul-03	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire
Jun-11	Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress FATE GlobeNewswire
May-30	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors FATE GlobeNewswire
May-28	Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress FATE GlobeNewswire
May-13	Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates FATE GlobeNewswire
May-02	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.